InflaRx NV has a consensus price target of $8.2 based on the ratings of 6 analysts. The high is $19 issued by Raymond James on November 2, 2023. The low is $2 issued by Credit Suisse on May 13, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 24, 2024, June 6, 2024, and May 9, 2024, respectively. With an average price target of $8 between HC Wainwright & Co., there's an implied 396.89% upside for InflaRx NV from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/24/2024 | Buy Now | 396.89% | HC Wainwright & Co. | Edward White | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
06/06/2024 | Buy Now | 396.89% | HC Wainwright & Co. | Edward White | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
05/09/2024 | Buy Now | 396.89% | HC Wainwright & Co. | Edward White | → $8 | Reiterates | Buy → Buy | Get Alert |
03/22/2024 | Buy Now | 396.89% | HC Wainwright & Co. | Edward White | — | Reiterates | Buy → Buy | Get Alert |
01/25/2024 | Buy Now | 396.89% | HC Wainwright & Co. | Edward White | $9 → $8 | Maintains | Buy | Get Alert |
11/02/2023 | Buy Now | 1080.12% | Raymond James | Steven Seedhouse | $21 → $19 | Maintains | Strong Buy | Get Alert |
09/12/2023 | Buy Now | 459.01% | HC Wainwright & Co. | Edward White | → $9 | Reiterates | Buy → Buy | Get Alert |
08/31/2023 | Buy Now | 459.01% | HC Wainwright & Co. | Edward White | → $9 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | 459.01% | HC Wainwright & Co. | Edward White | → $9 | Reiterates | Buy → Buy | Get Alert |
05/12/2023 | Buy Now | 459.01% | HC Wainwright & Co. | Edward White | → $9 | Reiterates | Buy → Buy | Get Alert |
05/12/2023 | Buy Now | 1204.35% | Raymond James | Steven Seedhouse | $25 → $21 | Maintains | Strong Buy | Get Alert |
04/21/2023 | Buy Now | 459.01% | HC Wainwright & Co. | Edward White | $10 → $9 | Maintains | Buy | Get Alert |
04/06/2023 | Buy Now | 1452.8% | Raymond James | Steven Seedhouse | $8 → $25 | Maintains | Strong Buy | Get Alert |
04/05/2023 | Buy Now | 396.89% | Guggenheim | Yatin Suneja | → $8 | Upgrade | Neutral → Buy | Get Alert |
04/05/2023 | Buy Now | 521.12% | HC Wainwright & Co. | Edward White | $6 → $10 | Reiterates | → Buy | Get Alert |
04/05/2023 | Buy Now | — | LifeSci Capital | Sam Slutsky | — | Upgrade | Market Perform → Outperform | Get Alert |
03/23/2023 | Buy Now | 272.67% | HC Wainwright & Co. | Edward White | → $6 | Reiterates | → Buy | Get Alert |
01/06/2023 | Buy Now | 272.67% | HC Wainwright & Co. | Edward White | $8 → $6 | Maintains | Buy | Get Alert |
11/10/2022 | Buy Now | 396.89% | Raymond James | Steven Seedhouse | $7 → $8 | Maintains | Strong Buy | Get Alert |
08/08/2022 | Buy Now | 396.89% | HC Wainwright & Co. | Edward White | $7 → $8 | Maintains | Buy | Get Alert |
05/13/2022 | Buy Now | 24.22% | Credit Suisse | Tiago Fauth | $2.5 → $2 | Maintains | Underperform | Get Alert |
05/13/2022 | Buy Now | 334.78% | Raymond James | Steven Seedhouse | $15 → $7 | Maintains | Strong Buy | Get Alert |
05/13/2022 | Buy Now | 334.78% | HC Wainwright & Co. | Edward White | $11 → $7 | Maintains | Buy | Get Alert |
05/12/2022 | Buy Now | 148.45% | SVB Leerink | Joseph Schwartz | $6 → $4 | Maintains | Outperform | Get Alert |
03/25/2022 | Buy Now | 272.67% | SVB Leerink | Joseph Schwartz | $8 → $6 | Maintains | Outperform | Get Alert |
11/08/2021 | Buy Now | 831.68% | Raymond James | Steven Seedhouse | — | Maintains | Strong Buy | Get Alert |
10/28/2021 | Buy Now | 769.57% | Raymond James | Steven Seedhouse | — | Upgrade | Outperform → Strong Buy | Get Alert |
08/06/2021 | Buy Now | 521.12% | Raymond James | Steven Seedhouse | — | Maintains | Outperform | Get Alert |
08/06/2021 | Buy Now | 55.28% | Credit Suisse | Tiago Fauth | — | Maintains | Underperform | Get Alert |
The latest price target for InflaRx (NASDAQ:IFRX) was reported by HC Wainwright & Co. on June 24, 2024. The analyst firm set a price target for $8.00 expecting IFRX to rise to within 12 months (a possible 396.89% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for InflaRx (NASDAQ:IFRX) was provided by HC Wainwright & Co., and InflaRx reiterated their buy rating.
The last upgrade for InflaRx NV happened on April 5, 2023 when Guggenheim raised their price target to $8. Guggenheim previously had a neutral for InflaRx NV.
There is no last downgrade for InflaRx.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InflaRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InflaRx was filed on June 24, 2024 so you should expect the next rating to be made available sometime around June 24, 2025.
While ratings are subjective and will change, the latest InflaRx (IFRX) rating was a reiterated with a price target of $8.00 to $8.00. The current price InflaRx (IFRX) is trading at is $1.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.